Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=330

A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan

Multiple Myeloma

Bottom Line

View on ClinicalTrials.gov: NCT05882279 ↗
Enrolled (actual)
330
Serious AEs
—
Results posted
Jun 2024
Primary outcome: Primary: Number of Pharmacists Who Had Provided Patients With the Contents of the Risk Management Plan (RMP) Material — 307 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
No Intervention (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Takeda
Primary completion
Jun 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Pharmacists Who Had Provided Patients With the Contents of the Risk Management Plan (RMP) Material		 307 —
SECONDARY
Number of Pharmacists Who Had Received the RMP Material for Patients		 124 —
SECONDARY
Number of Pharmacist With Understanding of the Proper NINLARO Dosing Schedule		 316 —
SECONDARY
Number of Pharmacist With Understanding of the Importance of Providing NINLARO Dosing Schedule		 298; 30; 1; 1 —

Summary

This is a survey among pharmacists who have instructed NINLARO therapy in ixazomib, lenalidomide and dexamethasone (IRD) dosing to patients with relapsed/refractory multiple myeloma (rrMM). The main aims of the study are: * To assess the frequency of pharmacists who have provided patients with the contents of the RMP material for patients. * To assess the frequency of pharmacists who have obtained the RMP material for patients. * To evaluate the depth of understanding of proper usage of NINLARO among pharmacists.

Eligibility Criteria

Inclusion criteria

  • Who belong to hospitals prescribing NINLARO.
  • Who have instructed the dosing of NINLARO in IRD therapy to patients.

Exclusion criteria

None

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05882279). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search